Paysign Q3 revenue up 17% to $12.4M; net income $1.1M; pharma revenue +142%

Paysign, Inc.

2023-Q3 EPS reported $0.02 revenue$33,584,666

Q3 total revenues $12.4M (+17% YoY); net income $1.1M, diluted EPS $0.02.
Adjusted EBITDA $2.3M (+22% YoY); plasma revenue +13%, pharma patient affordability revenue +142%.
Added 19 new plasma centers (462 total); avg revenue per plasma center per month $8,102 (+7.8% YoY).
Exited quarter with $9.9M unrestricted cash, zero debt; repurchased 75k shares for $150k.
FY2023 guidance reaffirmed: revenue $44-46M, Adj. EBITDA $6-7.5M; Q4 growth expected slightly above 17%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Paysign, Inc. reported financial results for the fiscal quarter ended September 30, 2023.

Period: the fiscal quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, we issued a press release regarding our financial results for the fiscal quarter ended September 30, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Paysign, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-007671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.